CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD) ChapterEspicom Healthcare IntelligenceNovember 27, 2006 84 Pages - SKU: ESPI1392159 |
| ADHD is now the 9th largest segment of the CNS market by sales with growth of 8% year-on-year. Find out more in this chapter of CNS Drug Discoveries.
The value of the ADHD market was US$2.6 billion in 2005 and it is now the 9th largest segment of the CNS market by sales with growth of 8% year-on-year. Global sales of ADHD drugs are forecast to reach US$4.3 billion by 2012. This will be due to greater penetration in the treatment of new patients, particularly adult ADHD, improvements in patient compliance due to the launch of new formulations, new non-schedule II drugs and the development of novel classes of drugs in late-stage clinical trials. There has been a significant increase in ADHD diagnosis and prescription of medicine since the early 1990s due to wider understanding of the condition in the mental health community, increased use of medication and healthcare coverage and the launch of ADHD-specific drugs (from 2000 onwards). ADHD is one of the most common psychiatric disorders of childhood and approximately 50% to 70% of children with ADHD will continue to experience symptoms into adulthood. In 2000, it was estimated that 4-5 million individuals (mainly children) were diagnosed with ADHD of whom 75-85% were treated with psychostimulants. Over 8 million adults in the US may exhibit the symptoms of ADHD, while only an estimated 600,000 are being treated. Global ADHD market Approximately 90% of ADHD global sales were derived from the US in 2005, with the remainder from Europe. This is largely due to a higher diagnosis rate in paediatrics and availability of drugs for medical reimbursement. Growth in adult ADHD medications has increased exponentially whilst their use in children has slowed due to safety concerns. Growth has also been driven by the launch of new non-stimulant drugs, new patients and the development of new formulations providing flexibility in dosing and higher patient compliance. This has helped to offset the impact of generics which are beginning to emerge on the market. Key questions answered in this chapter include:
|
Additional Information
Tables Charts & Figures
- Symptoms of ADHD by subtype
- Patient population forecast to 2012 by type showing % diagnosed and treated (children and adults)
- US market share for ADHD drugs for 6 leading companies
- European market share for ADHD drugs for 5 leading companies
- Comparison of leading ADHD drugs
- Patent exposure of leading ADHD brands
- Competitor analysis of currently available therapies
- Forecast of global drug sales by year to 2012
- Drugs in development to treat ADHD
- Forecast global sales by year to 2012 of new drugs: Connexyn (Shire), NRP104 (Shire) and SPD465 (Shire)
- Competitor analysis of upcoming products of note: NS2359 (NeuroSearch/GlaxoSmithKline) and CX7171 (Cortex)
- Competitor ratio analysis of drugs and companies
- Winners & losers in the ADHD market
- Discontinued ADHD drugs
Related Markets
Behavioral Health Reports
- Key Companies: Depression - Leading players must adapt to remain competitive
- CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players
- Product Profiles: Depression - Next generation vies for second-line patients
- Alcohol Addiction Global Clinical Trials Review, Q2, 2011
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
